---
figid: PMC7350257__ijms-21-04507-g003
figtitle: PI3K-AKT-mTOR and AR signaling crosstalk facilitates resistance to androgen/AR
  and AKT-directed monotherapy
organisms:
- NA
pmcid: PMC7350257
filename: ijms-21-04507-g003.jpg
figlink: pmc/articles/PMC7350257/figure/ijms-21-04507-f003/
number: F3
caption: PI3K-AKT-mTOR and AR signaling crosstalk facilitates resistance to androgen/AR
  and AKT-directed monotherapy. Schematics depict reported model mechanisms for therapeutic
  resistance to (A) androgen/AR-directed therapy, which leads to increased AKT activation,
  and (B) AKT inhibition. AD, androstenedione; CYP17A1, cytochrome P450 17A1; DHEA,
  dehydroepiandrosterone; Ub, ubiquitination event.
papertitle: 'The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR,
  MAPK, and WNT Signaling.'
reftext: Boris Y. Shorning, et al. Int J Mol Sci. 2020 Jun;21(12):4507.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9750212
figid_alias: PMC7350257__F3
figtype: Figure
organisms_ner:
- Danio rerio
- Homo sapiens
redirect_from: /figures/PMC7350257__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7350257__ijms-21-04507-g003.html
  '@type': Dataset
  description: PI3K-AKT-mTOR and AR signaling crosstalk facilitates resistance to
    androgen/AR and AKT-directed monotherapy. Schematics depict reported model mechanisms
    for therapeutic resistance to (A) androgen/AR-directed therapy, which leads to
    increased AKT activation, and (B) AKT inhibition. AD, androstenedione; CYP17A1,
    cytochrome P450 17A1; DHEA, dehydroepiandrosterone; Ub, ubiquitination event.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - cyp17a1
  - ar
  - hsp90aa1.1
  - fkbp5
  - her2
  - her3
  - erbb2
  - slc43a1a
  - CYP17A1
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPTOR
  - AR
  - HSP90AA1
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - PHLPP1
  - FKBP5
  - KLK3
  - KLKB1
  - ERBB2
  - ERBB3
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - SLC43A1
  - Androgen
  - Progesterone
  - Pregnenolone
  - H Abiraterone
  - DHEA
  - DHT DHT
  - Enzalutamide
  - H
  - cancer
---
